Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT387 dose-escalation and dose-confirmation study in myelofibrosis
ACTRN12611000159954Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of mivavotinib in primary myelofibrosis (PMF) and myelofibrosis (MF) (8 arms), sponsored by Gilead Sciences. Primary endpoints: Safety, tolerability, dose-limiting toxicities and maximum tolerated dose, Objective response rate and 1 more. Started Aug 2011; status: completed.
02
Drugs
mivavotinib
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on ACTRN12611000159954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000159954.